Laura Roca-Alonso
Chief Operating Officer bij E-THERAPEUTICS PLC
Profiel
Laura Roca-Alonso is currently the Chief Operating & Business Officer at e-Therapeutics Plc since 2020.
Prior to this, she worked as the VP & Head-Corporate Development at Silence Therapeutics Plc from 2004 to 2019.
She also worked as the Director-Business Development at Gyroscope Therapeutics Ltd.
Dr. Roca-Alonso holds a doctorate degree from Imperial College London, a graduate degree from University College London, and an undergraduate degree from Autonomous University of Barcelona.
Actieve functies van Laura Roca-Alonso
| Bedrijven | Functie | Begin |
|---|---|---|
| E-THERAPEUTICS PLC | Chief Operating Officer | 02-04-2020 |
Eerdere bekende functies van Laura Roca-Alonso
| Bedrijven | Functie | Einde |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 01-01-2019 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van Laura Roca-Alonso
| Imperial College London | Doctorate Degree |
| University College London | Graduate Degree |
| Autonomous University of Barcelona | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| E-THERAPEUTICS PLC | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Bedrijven in privébezit | 1 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
